ESMO: Regeneron Gets Encouraging Early Data For Bispecifics In Solid Tumors
More Evidence Needed For Big Picture
The company presented positive early data at ESMO for two bispecific antibodies that are important to the company's long-term business strategy, MUC16xCD3 and METxMET.
